e-learning
resources
Madrid 2019
Monday, 30.09.2019
COPD treatment: cohorts and real-world studies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The frequent exacerbator in real-life: an analysis of the DACCORD study
C. Vogelmeier (Marburg, Germany), C. Criée (Bovenden, Germany), H. Worth (Fuerth, Germany), V. Obermoser (Nuremberg, Germany), K. Berschneider (Nuremberg, Germany), P. Kardos (Frankfurt am Main, Germany), R. Buhl (Mainz, Germany)
Source:
International Congress 2019 – COPD treatment: cohorts and real-world studies
Session:
COPD treatment: cohorts and real-world studies
Session type:
Thematic Poster
Number:
2494
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Vogelmeier (Marburg, Germany), C. Criée (Bovenden, Germany), H. Worth (Fuerth, Germany), V. Obermoser (Nuremberg, Germany), K. Berschneider (Nuremberg, Germany), P. Kardos (Frankfurt am Main, Germany), R. Buhl (Mainz, Germany). The frequent exacerbator in real-life: an analysis of the DACCORD study. 2494
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The frequent exacerbator phenotype in asthma: a clinical characterization
Source: Virtual Congress 2020 – Phenotypes of obstructive diseases
Year: 2020
LATE-BREAKING ABSTRACT: The infrequent "frequent" exacerbator: An analysis of the SPIROMICS cohort
Source: International Congress 2016 – From pleura to bronchi: new insights
Year: 2016
Exacerbations in a cohort of COPD patients: frequent exacerbators characteristics after 1-year follow-up (EXACO study – interim analysis)
Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects
Year: 2008
The frequent exacerbator phenotype in bronchiectasis: predictors and particularities
Source: International Congress 2018 – The importance of the pulmonary function test in different clinical settings
Year: 2018
Variability of symptoms is common in severe COPD: a pan-European cross-sectional study
Source: Annual Congress 2009 - Exacerbations and characteristics of COPD
Year: 2009
Latent class analyses used to study phenotypes in severe COPD with exacerbation. A pilot study
Source: Annual Congress 2010 - Epidemiological data for smoking control
Year: 2010
The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma
Source: International Congress 2017 – Bronchial asthma management
Year: 2017
Predictor of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020
Year: 2020
Characteristics of "frequent exacerbators" in mild to moderate COPD patients.
Source: International Congress 2018 – COPD around the world
Year: 2018
Characteristics of asthma patients with frequent exacerbations – an observational study in Sweden
Source: International Congress 2017 – Primary care management of asthma and self-management of respiratory disease
Year: 2017
Stability of the frequent exacerbator – A Danish nationwide register-based study
Source: International Congress 2016 – Management of asthma and COPD in primary care
Year: 2016
Prevalence, characteristics and management of frequently exacerbating asthma patients: an observational study in Sweden (PACEHR)
Source: Eur Respir J, 52 (2) 1701927; 10.1183/13993003.01927-2017
Year: 2018
Risk factors associated with frequent exacerbations (FE) in severe asthma: a multicentre study in Japan
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Can we consider the "frequent exacerbator" a reliable COPD phenotype?
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Late-breaking abstract: The forgotten majority: A decrease in persistent but not in intermittent asthma in a large cohort study
Source: Annual Congress 2011 - Genetic and environmental risk factors for respiratory diseases
Year: 2011
E-cigarette use is most common in persistent smokers in a Swedish prospective population study
Source: International Congress 2019 – From the health effects of tobacco to the epidemiology of tobacco/electronic nicotine delivery system use
Year: 2019
Characterization of the “frequent exacerbator phenotype” over a period of 3 years: Palomb cohort
Source: International Congress 2019 – More and more COPD
Year: 2019
Devise use errors among patients with asthma and COPD-A real-life study
Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Year: 2020
Exacerbation phenotypes of frequent versus non-frequent exacerbators among severe asthma patients
Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept